Cite
HARVARD Citation
Vergote, I. et al. (n.d.). 2022-RA-1548-ESGO Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: addition of a new cohort using first-line tisotumab vedotin + pembrolizumab + carboplatin ± bevacizumab in recurrent/metastatic cervical cancer. International journal of gynecological cancer. p. A64. [Online].